Skandinaviska Enskilda Banken AB publ Has $13.45 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Skandinaviska Enskilda Banken AB publ boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 59,391 shares of the medical instruments supplier’s stock after buying an additional 400 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Becton, Dickinson and Company were worth $13,453,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the period. E. Ohman J or Asset Management AB raised its holdings in Becton, Dickinson and Company by 13.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock worth $39,951,000 after buying an additional 20,859 shares during the period. Arete Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $767,000. Busey Bank raised its holdings in shares of Becton, Dickinson and Company by 3.8% in the fourth quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock valued at $15,031,000 after purchasing an additional 2,399 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the transaction, the executive vice president now directly owns 16,201 shares of the company’s stock, valued at $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,363 shares of company stock valued at $1,676,105 over the last ninety days. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $226.43 on Friday. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The firm has a fifty day simple moving average of $232.78 and a 200 day simple moving average of $232.37. The stock has a market capitalization of $65.02 billion, a PE ratio of 37.61, a P/E/G ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a share buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.84%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 69.10%.

Analyst Ratings Changes

BDX has been the topic of a number of recent research reports. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, March 5th. Barclays lifted their price objective on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.